NCT04465981View on ClinicalTrials.gov

Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients

UnknownOBSERVATIONAL

Enrollment

80

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

December 31, 2022

Conditions

COVID-19SARS-CoV-2 Infection

Interventions

DIAGNOSTIC_TEST

Sampling

Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.

Trial Locations (1)

85712

RECRUITING

TMC HealthCare, Tucson

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

TMC HealthCare

OTHER

lead

INanoBio Inc.

INDUSTRY